| Mrs Patience K Nixon, RN | |
|
1955 153rd Ln Nw, Andover, MN 55304-2591 | |
| (763) 528-1285 | |
| Not Available |
| Full Name | Mrs Patience K Nixon |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse |
| Location | 1955 153rd Ln Nw, Andover, Minnesota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104430180 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | 2479529 (Minnesota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Patience K Nixon, RN 1955 153rd Ln Nw, Andover, MN 55304-2591 Ph: (763) 528-1285 | Mrs Patience K Nixon, RN 1955 153rd Ln Nw, Andover, MN 55304-2591 Ph: (763) 528-1285 |
News Archive
Throughout Asia, humans and monkeys live side-by side in many urban areas. An international research team from the University of Washington, Fred Hutchinson Cancer Research Center and Jahangirnagar University has been examining transmission of a virus from monkeys to humans in Bangladesh, one of the world's most densely populated countries.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc. (NASDAQ:APCVZ), announced today that it has received approval from the US Food and Drug Administration (FDA) to market idarubicin hydrochloride injection in three dosage strengths (5mg/5mL, 10mg/10mL and 20mg/20mL). Idarubicin is therapeutically equivalent to the reference drug Idamycin PFS injection, which is marketed by the innovator Pfizer, Inc.
Biotechnology industry leaders announced today a major new program to improve the quality of U.S. life science education. The Biotechnology Institute's new "Scientists in the Classroom" initiative is the life science industry's response to President Obama's "Educate to Innovate" campaign to improve the performance of America's students in science, technology, engineering, and mathematics (STEM) education.
Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that the United States Food and Drug Administration (FDA) has approved SURFAXIN (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS.
Technology has made it possible to synthesize increasingly targeted drugs. But scientists still have much to learn from Mother Nature. Pyridomycin, a substance produced by non-pathogenic soil bacteria, has been found to be a potent antibiotic against a related strain of bacteria that cause tuberculosis.
› Verified 6 days ago
Rhonda Gaetano, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1529 140th Ln Nw, Andover, MN 55304 Phone: 763-498-3123 | |
Barbara Schiefen, Registered Nurse Medicare: Accepting Medicare Assignments Practice Location: 15245 Bluebird St Nw, Healthpartners Riverway Andover Urgent Care, Andover, MN 55304 Phone: 952-853-8800 | |
Miriam Orucho, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 2234 145th Ave Nw, Andover, MN 55304 Phone: 763-516-8536 | |
Jacob Alan Krebs, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 3679 173rd Ln Nw, Andover, MN 55304 Phone: 763-238-2499 | |
Jared Joshua Vidervol, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 725 148th Ln Nw, Andover, MN 55304 Phone: 763-548-4294 | |
Angela Elliott, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 4954 170th Ln Nw, Andover, MN 55304 Phone: 763-286-3862 Fax: 763-206-8393 |